KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ginkgo Bioworks Holdings (DNA) EBT: 2020-2025

Historic EBT for Ginkgo Bioworks Holdings (DNA) over the last 5 years, with Sep 2025 value amounting to -$80.8 million.

  • Ginkgo Bioworks Holdings' EBT fell 42.23% to -$80.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$340.1 million, marking a year-over-year increase of 47.81%. This contributed to the annual value of -$547.5 million for FY2024, which is 38.68% up from last year.
  • Latest data reveals that Ginkgo Bioworks Holdings reported EBT of -$80.8 million as of Q3 2025, which was down 33.29% from -$60.6 million recorded in Q2 2025.
  • In the past 5 years, Ginkgo Bioworks Holdings' EBT registered a high of -$54.9 million during Q2 2021, and its lowest value of -$1.6 billion during Q4 2021.
  • Over the past 3 years, Ginkgo Bioworks Holdings' median EBT value was -$165.9 million (recorded in 2024), while the average stood at -$152.1 million.
  • As far as peak fluctuations go, Ginkgo Bioworks Holdings' EBT slumped by 3,361.18% in 2021, and later soared by 88.30% in 2022.
  • Ginkgo Bioworks Holdings' EBT (Quarterly) stood at -$1.6 billion in 2021, then spiked by 88.30% to -$187.8 million in 2022, then fell by 12.80% to -$211.9 million in 2023, then skyrocketed by 49.10% to -$107.9 million in 2024, then crashed by 42.23% to -$80.8 million in 2025.
  • Its EBT stands at -$80.8 million for Q3 2025, versus -$60.6 million for Q2 2025 and -$90.9 million for Q1 2025.